39 + 0.00535 × moxifloxacin concentration, and c ΔΔQTcI = 2.36 + 0.00470 × moxifloxacin www.selleckchem.com/products/DAPT-GSI-IX.html concentration (open circle 400 mg, solid circle

800 mg) Fig. 4 Comparison of pre-dose baseline-corrected (solid circle) and time-matched (open circle) ΔΔQTcI (mean differences with 90 % confidence intervals) in a the moxifloxacin 400-mg group and b the moxifloxacin 800-mg group Differences among study centers, sequence groups, periods, and treatment-time interaction did not influence the variation in QTc prolongation (data not shown). QTc prolongation was affected by the different treatments, (i.e., moxifloxacin 400 or 800 mg) and by time (both P < 0.0001). 3.3 Pharmacokinetic Analyses Dose-dependent PK profiles were observed in the moxifloxacin concentration-time profiles (Fig. 5). BKM120 nmr The median value for T max was slightly greater in the moxifloxacin 800-mg group than in the moxifloxacin 400-mg

group. Certain parameters, such as t 1/2, CL/F, and Vd/F did not significantly differ between the treatment groups, while other parameters, such as C max and AUClast, tended to increase two-fold as the dose doubled (data not shown). Fig. 5 Plasma concentration-time profiles after a single oral administration of moxifloxacin 3.4 Safety Assessments A total of 14 subjects reported 11 adverse events, which included chest discomfort, chill, diarrhea, dizziness, dry mouth, epistaxis, fever, nausea, paresthesia, pruritis, and rhinorrhea. Among these, chest discomfort, diarrhea, and nausea were assessed to be either possibly or probably related to moxifloxacin. No serious adverse events were reported and all of the reported adverse events disappeared spontaneously. 4 Discussion Our study found ATR inhibitor a definite prolongation of the QTc interval after moxifloxacin dosing [11.66 ms in the moxifloxacin 400-mg

group and 20.96 ms in the moxifloxacin 800-mg group (QTcI values)]. The mean differences and 90 % CIs of ΔΔQTcI did not include zero at any of the measurement time points. A positive relationship between QT interval prolongation and moxifloxacin concentration (r = 0.422 in ΔΔQTcI) was also observed. The T max of moxifloxacin 400 and 800 mg occurred 1 and 3 h after dosing, respectively, whereas the largest time-matched ΔΔQTc Chlormezanone was measured approximately 4 h after dosing. Moxifloxacin 400 mg is known to cause a mean increase in the QTc interval of between 10 and 14 ms 2–4 h after a single oral dose [4, 8], which was consistent with the results of this study. In addition, a supratherapeutic dose of moxifloxacin (800 mg) resulted in a nearly 2-fold increase in the QTc interval from baseline compared with the 400-mg dose, which was greater than the previous report by Demolis et al. [4]. Although Demolis et al. only used QTcB and QTcF values in their study, they found no relationship between the dose of moxifloxacin and QT interval lengthening, but found a positive relationship between QT interval prolongation and moxifloxacin concentration [r = 0.